Therapeutics

LUSTGARTEN FUNDED RESEARCH: An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk […]

LUSTGARTEN FUNDED RESEARCH: A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig […]

LUSTGARTEN FUNDED RESEARCH: Researchers at the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research have found two enzymes that work against the chemotherapy drug gemcitabine, preventing it from effectively treating […]

Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at Memorial Sloan Kettering Cancer Center, New York, United States. Autogene […]

Research by Oregon State University has uncovered a potential new therapy for pancreatic cancer, whose survival rate is among the lowest of all malignancies.

When you’re facing a pancreatic cancer diagnosis, humor may be tough to come by. Instead, feelings of grief, sadness, depression and anxiety become so all-consuming that getting a chuckle from […]

Results from an ongoing phase 2b GRECO-2 clinical trial show that the novel drug GC4419 may be promising in treating patients with unresectable or borderline resectable locally advanced pancreatic cancer […]

By Ellen Zimmerman The Therapeutics-Focused Research Program will advance the understanding of the causes and progression of pancreatic cancer and will identify new potential therapies. This grant program will stimulate […]